Lee MY, et al. – An analysis was performed to determine the persistence of adalimumab, etanercept, infliximab, or abatacept as first– and subsequent–line treatment for rheumatoid arthritis in the South Korean. When used as first–line treatment, adalimumab, etanercept, and infliximab had similar levels of persistence during the 1–year after treatment initiation. Whereas, when used as a subsequent–line treatment, etanercept and abatacept had higher persistence than infliximab or adalimumab. Persistence could be helpful when selecting the subsequent–line biologic treatment for patients with rheumatoid arthritis in South Korea.